Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Latest Financial Report
Interim Report Q4 2022 incl. Full Year Report, January 26
PDF | AudioCast | Presentation

Latest presentations

Analyst reports

Investment themes
Latest CEO Comments

JANUARY 26, 2023
"Well positioned to capture new market opportunities and reach profitability "
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Invitation to presentation of Orexo´s Interim Report Q4 2022 incl. Full Year Report
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
Edward Kim, M.D., Chief Medical Officer: “I joined Orexo to make a difference in the lives of people suffering from opioid use disorder”
Key financial figures
Group net revenue
Group EBITDA
US Pharma segment EBIT
Cash position
